Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure†-Reference-Cited by-同舟云学术

Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure†

Published:2010-02 Issue:1-2 Volume:1 Page:24-36
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:

Author:

Nauck Michael A,Vardarli Irfan

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.2040-1124.2010.00004.x/fullpdf

Reference81 articles.

1. Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes;Nauck;Regul Pept,2005

2. Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?;Nauck;Best Pract Res Clin Endocrinol Metab,2009

3. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors;Deacon;Diabetes Obes Metab,2007

4. Biology of incretins: GLP-1 and GIP;Baggio;Gastroenterology,2007

5. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet,2006

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feline comorbidities: Pathophysiology and management of the obese diabetic cat;Journal of Feline Medicine and Surgery;2021-06-25

2. Drug discovery for type 2 diabetes mellitus and metabolic syndrome: ten novel biological targets;Diabetes mellitus;2015-03-18

3. Agonistes du récepteur du GLP-1 en une injection hebdomadaire : quelles perspectives pour le patient diabétique de type 2 ?;Médecine des Maladies Métaboliques;2014-12

4. Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males: A Randomized, Single-Blind, Placebo-Controlled Trial;Advances in Therapy;2014-02-18

5. Aerosolized GLP-1 for Treatment of Diabetes Mellitus and Irritable Bowel Syndrome;Advances in Experimental Medicine and Biology;2014